The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 14.1 billion by 2030 and is projected to grow at a CAGR of 2.5% till 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn’s disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.
Get deeper insights, latest developments & key market drivers in the U.S. Inflammatory Bowel Disease Treatment Market
Market Report Highlights
• Based on type, the Crohn’s disease segment dominated the market with the largest revenue share.
• On the other hand, the ulcerative colitis segment is expected to register the fastest CAGR during the forecast period, owing to its increasing incidence rate.
• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share, due to their effectiveness in managing the symptoms and reducing inflammation.
• Based on route of administration, the injectable segment held the largest market share.
Key U.S. Inflammatory Bowel Disease Treatment Company Insights
Some of the key companies operating in the U.S. marketinclude AbbVie, Inc.; Takeda Pharmaceutical Company Limited, Pfizer, Inc.; and Novartis AG.
Recent Developments
• In October 2023, the FDA approved Novartis Cosentyx. It was the first new biologic treatment option for hidradenitis suppurativa in adult patients.
• In May 2023, Amgen and Tscan Therapeutics collaborated to identify the integration of the novel targets in Crohn’s disease. It created a platform that offered target discovery and improved Amgen's inflammation therapeutic expertise and capabilities.
• In December 2021, Novartis announced that the U.S. FDA approved Cosentyx for the treatment of active enthesitis-related arthritis. These regulatory trials helped the market to expand its share.
• In April 2021, the U.S. FDA approved Bristol Myers Squibb’s Zeposia (ozanimod), an oral treatment for adults with active ulcerative colitis.
Looking for U.S. Inflammatory Bowel Disease Treatment Market Research Report? Get your free sample PDF with key data & latest trends.
Key questions answered in this report
• How big is the U.S. IBD treatment market?
• What is the U.S. IBD market growth?
• Which segment accounted for the largest U.S. IBD treatment market share?
• Who are the key players in the U.S. IBD treatment market?
• What are the factors driving the U.S. IBD treatment market?